GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (OTCPK:BPMUF) » Definitions » Short Interest

BPMUF (Basilea Pharmaceutica) Short Interest


View and export this data going back to 2004. Start your Free Trial

What is Basilea Pharmaceutica Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Basilea Pharmaceutica's Short Interest

For the Biotechnology subindustry, Basilea Pharmaceutica's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basilea Pharmaceutica's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Short Interest distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Short Interest falls into.


Basilea Pharmaceutica Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (OTCPK:BPMUF) » Definitions » Short Interest
Comparable Companies
XSWX:IDIA XSWX:MOLN XSWX:NWRN XSWX:XLS XSWX:SANN XSWX:RLF XSWX:ADXN VRTX REGN ASX:CSL XKRX:207940 XBRU:UCB ALNY XBRU:ARGX XKRX:068270 BNTX BGNE MRNA SMMT UTHR
Traded in Other Exchanges
BSLNz:UK 0QNA:UK BSLN:Switzerland
Address
Hegenheimermattweg 167b, Allschwil, CHE, 4123
Website
https://www.basilea.com
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.